Integrin alpha V beta 5

Integrin alpha V beta 5 Overview

English NameIntegrin alpha-V/beta-5Approved Drugs0
Drugs in Clinical Trials3Target SynonymReceptors, Vitronectin
Highest Development StagePhase 1 Clinical
English NameIntegrin alpha-V/beta-5
Target SynonymReceptors, Vitronectin
Approved Drugs0
Drugs in Clinical Trials3
Highest Development StagePhase 1 Clinical

Integrin alpha V beta 5 Background

Integrin alpha V beta 5 (ITGAV & ITGB5) is expressed on a wide variety of cell types including keratinocytes, fibroblasts, adhesive monocytes, embryonic stem cells, and select endothelium and epithelium. ITGAV & ITGB5 binds ligands containing an RGD motif, notably vitronectin. Growth factors that increase PKC activity, such as VEGF or TGF alpha, promote ITGAV & ITGB5-mediated angiogenesis while alpha V beta 3, which may be expressed in the same cell, responds to FGF-basic and TNF alpha. An inhibitor of both down regulates tumor angiogenesis. During lung inflammation, up regulation of ITGAV & ITGB5 on myofibroblasts or infiltrating lymphocytes may contribute to fibrosis by freeing TGF beta from latency.

Integrin alpha V beta 5 Synonyms

Integrin alpha V beta 5,ITGAV&ITGB5

Clinical Drug Information

English NameResearch CodeHighest Development StageCompanyIndicationClinical Trial
RisuteganibALG-1001; AM011; AM-011(Allegro Ophthalmics)Phase 1 ClinicalAllegro Ophthalmics LlcDiabetic macular oedema; Diabetic Retinopathy; Geographic Atrophy; Macular Degeneration
Details
177Lu-FF-10158177Lu-FF-10158Phase 1 ClinicalFujifilm Holdings CorpGlioblastoma
Details
NP-011NP-011Phase 1 ClinicalNexell Therapeutics IncMyocardial Infarction
Details
  • Overview
  • Product List
  • Clinical Drug Information
Contact Us

[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521

[North America]: 1 Innovation Way, Newark, DE 19711, USA
[Switzerland]: ACRObiosystems AG, c/o Zug Dammstrasse Centre AG, Dammstrasse 19, 6300 Zug Switzerland